Abstract
Since HIV-1 was first discovered in the early 1980s, this virus has killed nearly 400,000 people around the world. However, up to now, there is no known cure for HIV-1 infection, because the removal of the HIV-1 repository is unreachable. In recent years, scientists began to apply the chimeric antigen receptor (CAR), an immunotherapy that has made great progress in hematological malignancies treatment, to the remedy of people infected with HIV-1, hoping to "kill" the virus completely after "shock" treatment. This review discussed the latest research progress of different types of CAR T cells, including CD4-based, scFv-based, and bi-/tri-specific CAR T cells, in HIV-1 therapy, and their advantages and limitations in detail. Additionally, it also briefly reviewed the function of NK cells in fighting HIV-1 infection and summarized the research results of CAR NK cells in AIDS treatment.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
